



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar - 393 002, Gujarat
Corp Office : 701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058.
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 31 December, 2016

(Rs. In Lakhs)


Particulars	Quarter Ended			Nine Months Ended		Previous Year Ended
	31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 (a). Net Income from Sales / Services	1,810.57	1,864.97	1,654.23	5,802.94	4,188.16	6,185.52
(b). Other Operating Income	0.21	3.06	2.55	7.64	4.67	7.69
Total Income	1,810.78	1,868.03	1,656.78	5,810.58	4,192.83	6,193.21
2. Expenditure						
a) Cost of Materials Consumed	1,368.92	1,731.83	1,116.45	5,023.76	3,443.67	5,065.47
b) Purchase of Traded Goods	143.74	0.00	320.58	143.74	407.85	580.12
c) (Increase)/Decrease in Stock in Trade & WIP	63.10	(79.64)	73.17	16.72	(51.65)	(31.42)
d) Employee benefits expense	27.26	23.63	24.75	73.00	66.25	97.78
e) Depreciation	12.18	11.60	11.18	34.91	33.11	44.34
f) Other Expenditure						
(i) Manufacturing Expenses	51.61	60.10	42.27	167.84	137.06	210.26
(ii) Administration Expenses	12.61	25.23	12.95	51.17	44.40	57.79
(iii) Selling & Distribution Expenses	22.63	15.06	30.45	59.13	59.76	85.70
g) Total	1,702.05	1,787.81	1,631.80	5,570.27	4,140.45	6,110.04
3. Profit from Operations before Other Income, Interest and Exceptional Items	108.73	80.22	24.98	240.31	52.38	83.17
4. Other Income	1.10	(1.12)	4.19	5.21	11.41	12.97
5. Profit before Interest and Exceptional items	109.83	79.10	29.17	245.52	63.79	96.14
6. Finance Costs	15.74	24.03	22.65	57.16	40.44	50.86
7. Profit after Finance costs but before Exceptional items	94.09	55.07	6.52	188.36	23.35	45.28
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00	(0.42)
9. Profit / (Loss) from ordinary activities before tax	94.09	55.07	6.52	188.36	23.35	44.86
10. Tax expense (incl deferred tax)	(29.07)	(13.34)	(5.50)	(56.71)	(10.95)	(14.74)
11. Net Profit / (Loss) from ordinary activities after tax	65.02	41.73	1.02	131.65	12.40	30.12
12. Extraordinary Items (Net of tax expense Rs. ____)	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	65.02	41.73	1.02	131.65	12.40	30.12
14. Share of Profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16. Net Profit / (Loss) after tax, share of profit/loss of associates and minority interest	65.02	41.73	1.02	131.65	12.40	30.12
17. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
18. Reserves excluding revaluation reserves	1,198.29	1,133.27	1,048.91	1,198.29	1,048.91	1,066.64
19. Earnings per share						
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	2.10	1.35	0.03	4.26	0.40	0.97
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	2.10	1.35	0.03	4.26	0.40	0.97
20. Public shareholding						
-- Number of shares	1,611,753	1,622,521	1,631,553	1,611,753	1,631,553	1,628,282
-- Percentage of shareholding	52.17	52.51	52.81	52.17	52.81	52.70
21. Promoters and promoter group shareholding						
a) Pledged/ Encumbered						
-- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered						
-- Number of shares	1,477,947	1,467,179	1,458,147	1,477,947	1,458,147	1,461,418
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.83	47.49	47.19	47.83	47.19	47.30

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 31 December, 2016.
- The above results have been taken on record by the Board of Directors at its Meeting held on Tuesday, 14 February 2017 at the Corporate Office of the Company.
- Previous period / year's figures have been regrouped and rearranged wherever necessary.
- Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 December, 2016

Opening Balance as on	1-Oct-2016	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	31-Dec-2016	0

By order of the Board of Directors
For Samrat Pharmachem Limited


Rajesh Mehta
Director

Place : Mumbai
Date : 14 February 2017



LIMITED REVIEW REPORT

To Board of Directors
Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter and Nine months ended 31st December, 2016 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financials statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.
3. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & SAVLA LLP
Chartered Accountants
Firm Reg: No.:109364W

Mirala
14/02/2017
CA. Miral H. Nagda
(Partner)
Membership No. 108135



Place: Mumbai

Date: 14th February, 2017